{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003019","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.821409+00:00","generated_at":"2026-05-27T21:51:08.406198+00:00","sec_items":["1.01","2.03","2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage","bullets":["Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.","Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).","Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.","Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003019","json":"https://secwatch.observer/filing/0001493152-25-003019.json","markdown":"https://secwatch.observer/filing/0001493152-25-003019.md","text":"https://secwatch.observer/filing/0001493152-25-003019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/0001493152-25-003019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:51:08.406198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}